Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

被引:1195
|
作者
Falkenberg, Katrina J. [1 ]
Johnstone, Ricky W. [1 ,2 ]
机构
[1] Peter MacCallum Canc Ctr, Canc Therapeut Program, East Melbourne, Vic 3002, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3052, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
SUBEROYLANILIDE HYDROXAMIC ACID; TRANS-RETINOIC ACID; CELLS IN-VITRO; SPINAL MUSCULAR-ATROPHY; DOUBLE-STRAND BREAKS; VERSUS-HOST-DISEASE; HDAC INHIBITORS; GENE-EXPRESSION; VALPROIC ACID; EPIGENETIC REGULATION;
D O I
10.1038/nrd4360
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters. Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small molecules. This Review discusses the role of altered expression and/or function of one class of epigenetic regulators histone deacetylases (HDACs) - and their role in cancer, neurological diseases and immune disorders. We highlight the development of small-molecule HDAC inhibitors and their use in the laboratory, in preclinical models and in the clinic.
引用
收藏
页码:673 / 691
页数:19
相关论文
共 50 条
  • [1] Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
    Katrina J. Falkenberg
    Ricky W. Johnstone
    [J]. Nature Reviews Drug Discovery, 2014, 13 : 673 - 691
  • [2] Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
    Katrina J. Falkenberg
    Ricky W. Johnstone
    [J]. Nature Reviews Drug Discovery, 2015, 14 : 219 - 219
  • [3] Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders (vol 13, pg 673, 2014)
    Falkenberg, Katrina J.
    Johnstone, Ricky W.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (03) : 219 - 219
  • [4] Histone deacetylases and their inhibitors in inflammatory diseases
    Zhang, Sen-Yu
    Zhang, Li-Ying
    Wen, Ri
    Yang, Ni
    Zhang, Tie-Ning
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2024, 179
  • [5] The interplay between microRNAs and histone deacetylases in neurological diseases
    Bourassa, Megan W.
    Ratan, Rajiv R.
    [J]. NEUROCHEMISTRY INTERNATIONAL, 2014, 77 : 33 - 39
  • [6] Histone Deacetylases and Their Inhibitors in Cancer Epigenetics
    Hassell, Kelly N.
    [J]. DISEASES, 2019, 7 (04)
  • [7] Pharmacological inhibition a of histone deacetylases for the treatment of cancer, neurodegenerative disorders and inflammatory diseases
    Bonfils, Claire
    Walkinshaw, Donald R.
    Besterman, Jeffrey M.
    Yang, Xiang-Jiao
    Li, Zuomei
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (09) : 1041 - 1065
  • [8] The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
    Li, Guo
    Tian, Yuan
    Zhu, Wei-Guo
    [J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
  • [9] Histone Deacetylases Inhibitors in Neurodegenerative Diseases, Neuroprotection and Neuronal Differentiation
    Shukla, Surabhi
    Tekwani, Babu L.
    [J]. FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [10] Histone deacetylases inhibitors impair innate immune responses of macrophages
    Mombelli, M.
    Giddey, M.
    Knaup, Peymond M.
    Calandra, T.
    Roger, T.
    [J]. SWISS MEDICAL WEEKLY, 2007, 137 : 11S - 11S